ArticleExperimental hematology & oncology2026
ELK1 promotes the progress of myeloid leukemia by hindering the differentiation of neutrophils.
Article in Experimental hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe genes controlling lineage determination and differentiation tend to be essential for the development of acute myeloid leukemia (AML). Identifying novel target genes capable of promoting the differentiation and maturation of undifferentiated leukemia cells offers a promising therapeutic strategy for the treatment of AML.
methodsWe used conditional Elk1 and KrasG12D expression mice, along with Mx1-Cre, Lyz2-Cre and Elane-Cre drive strains (which enable stage specific control of Elk1 or KrasG12D expression), to investigate the function of Elk1 in the hematopoiesis and leukemogenesis. Bone marrow transplantation assay was performed to explore the function of Elk1 in hematopoiesis under stress conditions. Additionally, bulk-cell RNA sequencing, single-cell RNA sequencing and proteomics were performed to reveal the signaling pathways altered by Elk1. Finally, undifferentiated leukemia cells were used to verify whether inhibiting ELK1 could promote the differentiation of these cells into mature neutrophils.
resultsELK1 is highly expressed in undifferentiated AML cells. Studies using mouse model demonstrated that overexpression of Elk1 accelerates the development of KrasG12D-induced myeloid leukemia by impairing the stemness of hematopoietic stem cells (HSCs) and impeding the differentiation of neutrophils. Furthermore, impeding the maturation of neutrophils independently promotes the development of KrasG12D mutation-induced myeloid leukemia. Meanwhile, our in vitro experiments preliminarily confirmed that inhibiting ELK1 suppresses the proliferation of leukemia cells and induces the differentiation of CD15
conclusionsOur study demonstrates that ELK1 is a potential therapeutic target for AML, due to its critical role in regulating neutrophils differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.